FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361944776> ?p ?o ?g. }

• W4361944776 abstract "<div>Abstract<p><b>Purpose:</b> This phase I study investigated the maximum-tolerated dose (MTD), safety, pharmacodynamics, immunologic correlatives, and antitumor activity of CP-870,893, an agonist CD40 antibody, when administered in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDA).</p><p><b>Experimental Design:</b> Twenty-two patients with chemotherapy-naïve advanced PDA were treated with 1,000 mg/m² gemcitabine once weekly for three weeks with infusion of CP-870,893 at 0.1 or 0.2 mg/kg on day three of each 28-day cycle.</p><p><b>Results:</b> CP-870,893 was well-tolerated; one dose-limiting toxicity (grade 4, cerebrovascular accident) occurred at the 0.2 mg/kg dose level, which was estimated as the MTD. The most common adverse event was cytokine release syndrome (grade 1 to 2). CP-870,893 infusion triggered immune activation marked by an increase in inflammatory cytokines, an increase in B-cell expression of costimulatory molecules, and a transient depletion of B cells. Four patients achieved a partial response (PR). 2-[¹⁸F]fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography (FDG-PET/CT) showed more than 25% decrease in FDG uptake within primary pancreatic lesions in six of eight patients; however, responses observed in metastatic lesions were heterogeneous, with some lesions responding with complete loss of FDG uptake, whereas other lesions in the same patient failed to respond. Improved overall survival correlated with a decrease in FDG uptake in hepatic lesions (<i>R</i> = −0.929; <i>P</i> = 0.007).</p><p><b>Conclusions:</b> CP-870,893 in combination with gemcitabine was well-tolerated and associated with antitumor activity in patients with PDA. Changes in FDG uptake detected on PET/CT imaging provide insight into therapeutic benefit. Phase II studies are warranted. <i>Clin Cancer Res; 19(22); 6286–95. ©2013 AACR</i>.</p></div>" @default.
• W4361944776 created "2023-04-05" @default.
• W4361944776 creator A5001179545 @default.
• W4361944776 creator A5003671711 @default.
• W4361944776 creator A5013861799 @default.
• W4361944776 creator A5014753848 @default.
• W4361944776 creator A5019734570 @default.
• W4361944776 creator A5019995834 @default.
• W4361944776 creator A5028533192 @default.
• W4361944776 creator A5040750947 @default.
• W4361944776 creator A5058243523 @default.
• W4361944776 creator A5080030813 @default.
• W4361944776 creator A5088003622 @default.
• W4361944776 date "2023-03-31" @default.
• W4361944776 modified "2023-10-14" @default.
• W4361944776 title "Data from A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma" @default.
• W4361944776 doi "https://doi.org/10.1158/1078-0432.c.6522188" @default.
• W4361944776 hasPublicationYear "2023" @default.
• W4361944776 type Work @default.
• W4361944776 citedByCount "0" @default.
• W4361944776 crossrefType "posted-content" @default.
• W4361944776 hasAuthorship W4361944776A5001179545 @default.
• W4361944776 hasAuthorship W4361944776A5003671711 @default.
• W4361944776 hasAuthorship W4361944776A5013861799 @default.
• W4361944776 hasAuthorship W4361944776A5014753848 @default.
• W4361944776 hasAuthorship W4361944776A5019734570 @default.
• W4361944776 hasAuthorship W4361944776A5019995834 @default.
• W4361944776 hasAuthorship W4361944776A5028533192 @default.
• W4361944776 hasAuthorship W4361944776A5040750947 @default.
• W4361944776 hasAuthorship W4361944776A5058243523 @default.
• W4361944776 hasAuthorship W4361944776A5080030813 @default.
• W4361944776 hasAuthorship W4361944776A5088003622 @default.
• W4361944776 hasConcept C111113717 @default.
• W4361944776 hasConcept C112705442 @default.
• W4361944776 hasConcept C121608353 @default.
• W4361944776 hasConcept C126322002 @default.
• W4361944776 hasConcept C170493617 @default.
• W4361944776 hasConcept C2776694085 @default.
• W4361944776 hasConcept C2778938600 @default.
• W4361944776 hasConcept C2780210213 @default.
• W4361944776 hasConcept C2780258809 @default.
• W4361944776 hasConcept C2781182431 @default.
• W4361944776 hasConcept C2989005 @default.
• W4361944776 hasConcept C71924100 @default.
• W4361944776 hasConcept C90924648 @default.
• W4361944776 hasConceptScore W4361944776C111113717 @default.
• W4361944776 hasConceptScore W4361944776C112705442 @default.
• W4361944776 hasConceptScore W4361944776C121608353 @default.
• W4361944776 hasConceptScore W4361944776C126322002 @default.
• W4361944776 hasConceptScore W4361944776C170493617 @default.
• W4361944776 hasConceptScore W4361944776C2776694085 @default.
• W4361944776 hasConceptScore W4361944776C2778938600 @default.
• W4361944776 hasConceptScore W4361944776C2780210213 @default.
• W4361944776 hasConceptScore W4361944776C2780258809 @default.
• W4361944776 hasConceptScore W4361944776C2781182431 @default.
• W4361944776 hasConceptScore W4361944776C2989005 @default.
• W4361944776 hasConceptScore W4361944776C71924100 @default.
• W4361944776 hasConceptScore W4361944776C90924648 @default.
• W4361944776 hasLocation W43619447761 @default.
• W4361944776 hasOpenAccess W4361944776 @default.
• W4361944776 hasPrimaryLocation W43619447761 @default.
• W4361944776 hasRelatedWork W1971611596 @default.
• W4361944776 hasRelatedWork W2082064396 @default.
• W4361944776 hasRelatedWork W2117077603 @default.
• W4361944776 hasRelatedWork W2349340765 @default.
• W4361944776 hasRelatedWork W2365966720 @default.
• W4361944776 hasRelatedWork W2366580278 @default.
• W4361944776 hasRelatedWork W2370585970 @default.
• W4361944776 hasRelatedWork W2376347278 @default.
• W4361944776 hasRelatedWork W3032598722 @default.
• W4361944776 hasRelatedWork W3196960728 @default.
• W4361944776 isParatext "false" @default.
• W4361944776 isRetracted "false" @default.
• W4361944776 workType "article" @default.